Skip to Main Content

Paper Details

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Nat Med
25
2023
Author NameAffiliation
Kristi SunImperial College Healthcare NHS Trust
Lodewyk F A WesselsThe Netherlands Cancer Institute
Lodewyk F A WesselsOncode Institute, The Netherlands Cancer Institute
Lodewyk F A WesselsDelft University of Technology
Emile E VoestThe Netherlands Cancer Institute
Emile E VoestOncode Institute, The Netherlands Cancer Institute
  • 1 - 6

Datasets

Release 1.2